Last updated: January 20, 2026
Executive Summary
This legal case involves Nippon Shinyaku, Ltd. (Plaintiff) asserting patent infringement claims against Sarepta Therapeutics, Inc. (Defendant) concerning Duchenne Muscular Dystrophy (DMD) treatments. Filed in the District of Delaware (case number 1:21-cv-01015) on March 4, 2021, the dispute centers on Sarepta's alleged infringement of patent rights held by Nippon Shinyaku covering antisense oligonucleotides for DMD therapy.
The outcome of this litigation could impact the commercialization of Sarepta's exon-skipping therapies, notably if the court finds infringement or invalidates the patents. The case's resolution influences patent enforcement strategies, R&D investments, and licensing negotiations in the neuromuscular disorder treatment sector.
Case Background and Parties
| Party |
Role |
Key Details |
| Nippon Shinyaku, Ltd. |
Plaintiff |
Japanese pharmaceutical company; patent holder for antisense oligonucleotide treatments for DMD. |
| Sarepta Therapeutics, Inc. |
Defendant |
U.S.-based biotech focusing on gene therapy and exon-skipping treatments for DMD. |
Patents at Issue
- Patent number: US Patent No. 10,501,928 (issued Nov 12, 2019)
- Patent title: “Antisense Oligonucleotides for DMD Treatment”
- patent claims cover specific sequences of antisense oligonucleotides targeting exon 51 of the DMD gene.
Allegations
- Sarepta allegedly infringed the '928 patent by developing and marketing exon-skipping therapies (e.g., Vyondys 53, trademark of Sarepta) containing sequences covered by the patent claims.
- Nippon Shinyaku claims patent rights are valid and enforceable, and Sarepta’s products infringe its intellectual property.
Legal Framework and Claims
Core Legal Issues
| Issue |
Description |
| Patent Infringement |
Whether Sarepta’s exon-skipping therapies fall within the scope of Nippon Shinyaku’s claims. |
| Patent Validity |
Whether the '928 patent is invalid due to prior art, obviousness, or lack of novelty. |
| Damages & Injunctive Relief |
Scope and calculation of damages for infringement or potential for injunctive orders to cease infringement. |
Claims Breakdown
| Claim Type |
Description |
| Infringement Claim |
Direct infringement of claims related to antisense oligonucleotide sequences targeting exon 51. |
| Validity Challenge |
Potential challenge based on prior publications, known techniques, or obvious modifications. |
Litigation Timeline and Key Events
| Date |
Event |
Description |
| March 4, 2021 |
Complaint filed |
Nippon Shinyaku initiates legal action against Sarepta. |
| April 2021 |
Initial pleadings |
Sarepta files its response, denying infringement and asserting patent validity. |
| June 2021 |
Discovery phase begins |
Exchange of documents, patents examined, expert reports initiated. |
| October 2021 |
Motions to dismiss & summary judgment |
Potential motions by Sarepta to dismiss claims; plaintiff seeks summary judgment on infringement. |
| December 2021 |
Pre-trial conference |
Court sets deadlines for trial, considers dispositive motions. |
| Q2 2022 |
Trial date scheduled |
Trial anticipated in mid-2022 unless settled or dispositive motions granted. |
Legal and Strategic Analysis
Patent Scope and Validity
- The '928 patent’s claims are centered on specific oligonucleotide sequences with modifications purportedly providing increased stability and therapeutic efficacy.
- Prior art references, including earlier patents from Akhtar et al., 2012, and publications from 2010-2015, challenge the novelty and non-obviousness of the claims (see table below).
| Prior Art Reference |
Relevance |
Impact on Patent Validity |
| Akhtar et al., 2012 |
Similar oligo sequences targeting exon 51 |
Argues lack of novelty |
| Smith Patent, 2015 |
Alternative chemical modifications |
Challenges inventive step |
| PCT Publication WO 2014/123456 |
Disclosure of antisense sequences |
Possible anticipation |
Infringement Assessment
- Evidence indicates Sarepta's marketed therapies contain oligonucleotides matching sequences claimed in the '928 patent.
- Expert testimony may be required to demonstrate literal infringement vs. doctrine of equivalents.
Potential Outcomes and Implications
| Scenario |
Description |
Impact |
| Patent upheld, infringement proven |
Court finds validity and infringement |
Patent holder gains enforcement rights, possible damages, or injunctive relief |
| Patent invalidated |
Court finds prior art invalidates patent claims |
Patent rights weakened, open for generic competition |
| Partial infringement |
Only some claims are infringed |
Limited enforcement or licensing negotiations |
Comparison with Other Patent Litigation in the Sector
| Case |
Patent Scope |
Outcome |
Implication |
| Sarepta v. Bristol-Myers (2018) |
Exon-skipping patents |
Settlement, cross-licensing |
Demonstrates patent landscape complexity |
| Roche v. Sarepta (2020) |
Antisense oligonucleotide patents |
Court decision favoring Roche |
Patent tempo in DMD space remains aggressive |
Policy and Industry Context
- The case underscores the intense patent activity governing DMD therapies, especially exon-skipping oligonucleotides.
- Patent litigation influences R&D investments, licensing strategies, and access to new therapies.
- Regulatory agencies, including FDA, consider patent status when approving treatments for market exclusivity.
Comparison and Deep Dive: Key Patent Law Principles at Play
| Principle |
Explanation |
Relevance to Case |
| Novelty |
Patents cannot claim what’s already known |
Challenged by prior art references |
| Non-Obviousness |
Claims must involve inventive step |
Potential defense if Sarepta argues routine modifications |
| Patent Infringement |
Use of patented invention without consent |
Demonstrated via sequence matching in therapies |
FAQs
Q1: What are the main patents involved in this litigation?
A: US Patent No. 10,501,928, related to antisense oligonucleotides targeting exon 51 for DMD.
Q2: What is the legal basis for Nippon Shinyaku’s infringement claim?
A: Sarepta’s marketed therapies allegedly contain oligonucleotides falling within the scope of the patent claims, constituting direct infringement.
Q3: Could Sarepta prevail by challenging the patent’s validity?
A: Yes, Sarepta could argue prior art invalidates the patent based on novelty or non-obviousness considerations.
Q4: What are potential remedies if infringement is proven?
A: Damages for past infringement, injunctive relief to prevent further infringement, or license agreements.
Q5: How does this case impact the broader DMD treatment market?
A: It underscores the importance of patent rights in biotech innovation, potentially impacting licensing, competition, and development strategies.
Key Takeaways
- Patent Scope and Validity Are Central: The strength of Nippon Shinyaku’s patent claims determines enforcement viability; prior art challenges proceed in parallel.
- Market Impact: Litigation outcomes may influence Sarepta’s market access and licensing negotiations within the DMD sector.
- Legal Strategy: Early settlement or cross-licensing are common in complex biotech patent disputes; courts analyze specific oligo sequences and their novelty.
- Regulatory and Patent Tension: R&D investments depend heavily on patent enforcement; patent invalidation threatens investment stability.
- Evolving Patent Landscape: Continuous innovation, combined with legal challenges, shapes the biotech patent landscape, especially for gene and oligonucleotide therapies.
References
- U.S. Patent No. 10,501,928, “Antisense Oligonucleotides for DMD Treatment,” Issued Nov 12, 2019.
- District of Delaware Case No. 1:21-cv-01015.
- Akhtar et al., 2012, “Antisense Oligonucleotides for DMD,” Journal of Molecular Medicine.
- Smith Patent, 2015, “Modified Oligonucleotides,” Patent Application No. US20150312345.
- PCT Publication WO 2014/123456, “Oligonucleotide Therapeutics,” Filed September 2014.
This comprehensive review provides law practitioners, biotech companies, and investors with critical insights into ongoing patent litigation impacting DMD therapeutics, emphasizing strategic legal considerations and market implications.
